Literature DB >> 9365895

Antibodies against enteroviruses in intravenous Ig preparations: great variation in titres and poor correlation with the incidence of circulating serotypes.

J M Galama1, M T Vogels, G H Jansen, M Gielen, F W Heessen.   

Abstract

Antibody titres in immunoglobulin preparations for intravenous use were tested against 24 different enterovirus serotypes and varied between 1:100 and 1:10,000 within a single batch. Differences up to 8-fold were found for homologous titres between two different batches that were prepared 6 years apart. The lowest titre obtained was 1:40. The observed differences within and between the two batches could not be explained by different incidence of serotypes of enteroviruses circulating at the time blood was collected. Differences in titres of up to 18-fold were observed when several strains of the same serotype were tested suggesting that intratypic variation influences antibody titres. It is concluded that immunoglobulin preparations contain antibodies against many enteroviruses, but that titres can be low and cannot be predicted from the incidence of any particular serotype circulating in the community. Because of intratypic variation, selection of a batch for specific treatment should be based on results obtained with the patient's own isolate, and not with a reference strain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365895

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Extracorporeal life support for treatment of children with enterovirus 71 infection-related cardiopulmonary failure.

Authors:  Sheng-Ling Jan; Shing-Jong Lin; Yun-Ching Fu; Ching-Shiang Chi; Chung-Chi Wang; Hao-Ji Wei; Yen Chang; Betau Hwang; Po-Yen Chen; Fang-Liang Huang; Ming-Chih Lin
Journal:  Intensive Care Med       Date:  2009-12-24       Impact factor: 17.440

2.  Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses.

Authors:  Amy B Rosenfeld; Edmund Qian Long Shen; Michaela Melendez; Nischay Mishra; W Ian Lipkin; Vincent R Racaniello
Journal:  mBio       Date:  2022-01-18       Impact factor: 7.786

3.  Neutralising Antibodies against Enterovirus and Parechovirus in IVIG Reflect General Circulation: A Tool for Sero-Surveillance.

Authors:  Karen Couderé; Karlijn van der Straten; Lieke Brouwer; Gerrit Koen; Hetty van Eijk; Dasja Pajkrt; Jean-Luc Murk; Katja C Wolthers
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

4.  Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life.

Authors:  Jan Zoll; Sandra Erkens Hulshof; Kjerstin Lanke; Frans Verduyn Lunel; Willem J G Melchers; Esther Schoondermark-van de Ven; Merja Roivainen; Jochem M D Galama; Frank J M van Kuppeveld
Journal:  PLoS Pathog       Date:  2009-05-01       Impact factor: 6.823

5.  Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.

Authors:  Matthew S Buckland; James B Galloway; Caoimhe Nic Fhogartaigh; Luke Meredith; Nicholas M Provine; Stuart Bloor; Ane Ogbe; Wioleta M Zelek; Anna Smielewska; Anna Yakovleva; Tiffeney Mann; Laura Bergamaschi; Lorinda Turner; Frederica Mescia; Erik J M Toonen; Carl-Philipp Hackstein; Hossain Delowar Akther; Vinicius Adriano Vieira; Lourdes Ceron-Gutierrez; Jimstan Periselneris; Sorena Kiani-Alikhan; Sofia Grigoriadou; Devan Vaghela; Sara E Lear; M Estée Török; William L Hamilton; Joanne Stockton; Josh Quick; Peter Nelson; Michael Hunter; Tanya I Coulter; Lisa Devlin; John R Bradley; Kenneth G C Smith; Willem H Ouwehand; Lise Estcourt; Heli Harvala; David J Roberts; Ian B Wilkinson; Nick Screaton; Nicholas Loman; Rainer Doffinger; Paul A Lyons; B Paul Morgan; Ian G Goodfellow; Paul Klenerman; Paul J Lehner; Nicholas J Matheson; James E D Thaventhiran
Journal:  Nat Commun       Date:  2020-12-14       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.